Inclusion Criteria:  Male or female patients between 18-80 years' old Patients who have received a diagnosis of UC at least 3 months prior to screening. The diagnosis of UC must be confirmed by endoscopic and histologic evidence. Patients with the ability to give written informed consent and to be compliant with the schedule of intervention and assessments Patients with mild (3-5) or moderate (6-11) UC, according to the Simple Clinical Colitis Activity Index  Exclusion Criteria:  Pregnant patients or those planning pregnancy Patients receiving immunosuppressive agents for diseases other than UC Patients with confirmed cancer, dysplasia, autoimmune, and rheumatology diseases Patients who had surgery for UC treatment Individuals with liver disease or abnormal liver enzymes and function tests (e.g. total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) at the screening visit Patients who have any condition affecting oral drug absorption. Subjects with known active or untreated GI infections including C.diff, CMV, HSV, HIV Subjects with clinical features of CD; history of CD (Crohns colitis, or Ileo-colitis), clinical signs of fulminant colitis, toxic megacolon, or Microscopic Colitis, indeterminate Colitis, infectious Colitis, or ischemic colitis